Serum PLGF as a potential biomarker for predicting the onset of preeclampsia
Tóm tắt
Preeclampsia is one of the leading causes of maternal and perinatal morbidity and mortality. Till date despite years of research into the condition, predicting the onset of preeclampsia remains a problem. Placental growth factor is one of the many angiogenic factors, which shows significant altered levels in preeclampsia compared to normal pregnancy. The present study aims to analyze whether estimation of serum PLGF levels in late second trimester can act as a predictor of preeclampsia. A total of 150 nulliparous pregnant women admitted in antenatal wards or attending antenatal clinic were included in the study. They were divided into three groups: 30 women being normotensive and 60 each with diagnosed mild and severe preeclampsia, respectively. Serum samples collected from the study groups were subjected to ELISA, and serum PLGF level was calculated in all the samples. Mean serum PLGF levels were found to be significantly low in mild and severe preeclampsia as compared to normal pregnancy. Serum PLGF levels were highest at 26–28 weeks and were lowered at 28–30 and 30–32 weeks of gestation within each of the three study groups. Cutoff value of serum PLGF levels for predicting mild and severe preeclampsia was calculated statistically from the analyzed data. Estimation of serum PLGF levels at 26 weeks of gestation in nulliparous pregnant women can be used as a screening test to identify women at risk for the development of preeclampsia with very high sensitivity.
Tài liệu tham khảo
American College of Obstetricians and Gynecologists (2002). Diagnosis and management of preeclampsia. Practice bulletin, vol. 33.ACOG, Washington, DC
Sibai BM (1992) Hypertension in pregnancy. Obstet Gynecol Clin North Am 19:615–632
Cunningham FG Williams Obstetrics, 22nd edn, McGraw- Hill Medical Publishing Division. Hypertensive disorders in pregnancy. pp 761–808
Hauser S, Weich HA (1993) A heparin binding form of placenta growth factor (PLGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors 9:259–268
Maglione D, Guerriero V, Viglietto G, Delli Bovi P, Persico MG (1991) Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88:9267–9271
Quinn TP, Peters KG, De Vries C, Ferrara N, Williams LT (1993) Fetal liver kinase-1(Flk-1), the murine homologue of KDR exhibits high affinity binding to VEGF family of receptors. Proc Natl Acad Sci USA 90(4):7533–7537
Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NPW, Risau H, Ullrich A (1993) High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72(6):835–846
Ghosh D, Sharkey AM, Dhawan L, Dhara S, Smith SK (2000) Expression VEGF and PLGF in conceptus and endometrium during implantation in the rhesus monkey. Mol Hum Reprod 6:935–941
Krauss T, Pauer HU, Augustin HG (2004) Prospective analysis of PLGF concentration in the plasma of women with normal pregnancies complicated by preeclampsia. Hypertens Pregnancy 23(1):101–111
Torry DS, Wang HS, Wang TH, Candle MR, Torry RJ (1998) Preeclampsia is associated with reduced serum levels of placenta growth factor. AMJ Obstet Gynecol 179(6 Pt 1):1539–1544
Levine RJ, Maynard SE, Quin C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672–683
Roberts JM (1998) Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 16:5–15
Su YN, Lee CN, Cheng WF, Shau WY (2001) Decreased maternal serum placenta growth factor in early second trimester and preeclampsia. Obstet Gynecol 97(6):898–904
Jacquemyn Y, Zemtsova O (2010) Risk factors and prediction of preeclampsia. Acta Clin Belg 65(1):1–12
Stepan H, Jank A (2009) Angiogenic factors, their role in pathogenesis, prediction of preeclampsia. Z Geburtshilfe Neonatol 213(3):101–105
Robinson CJ, Johnson DD, Chang EY, Wang W (2006) Evaluation of PLGF and sFlt-1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 195(1):255–259
Reuvekamp A, VelsingAarts FV, Poulina IE, Capello J (1999) Selective deficit of angiogenic growth factors characterizes pregnancies complicated by preeclampsia. Br J Obstet Gynecol 106(10):1019–1022
Livingston JC, Chin R, Haddad B, Mckinney ET, Ahokas R, Sibai BM (2000) Reductions of VEGF and PLGF concentrations in severe preeclampsia. Am J Obstet Gynecol 183(6):1554–1557
Tjoa ML, John MG, Van vugt, Monique AM (2001) Plasma placenta growth factor levels in midtrimester pregnancies. Am Coll Obstet Gynecol 98(4):600–607
Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK (2003) Second trimester maternal serum PLGF and VEGF for predicting severe early onset preeclampsia. Obstet Gynecol 101(6):1266–1274
Thadani R, Mutter WP, Wolf M, Levine RJ, Taylor RN (2004) First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk factors for preeclampsia. J Clin Endocrinol Metabol 89(2):770–775
Park K (2005) Park’s textbook of preventive and social medicine, 18th edn, Banarsidas Bhanot publishers. Screening for disease pp 119–121
Schmidt M, Dogan C, Birdir C, Kuhn U, Kasimir-Bauer S (2009) Placental growth factor: a predictive marker for preeclampsia? Gynakol Geburtshilfliche Rundsch 49(2):94–99